To appraise the clinical and cost effectiveness of:Nivolumab in combination with rucaparib, docetaxel or enzalutamide within its marketing authorisation for prostate cancer
Status In progress
Process STA 2018
ID number 1621


Key events during the development of the guidance:

Date Update
05 September 2019 In progress, Referred 29 April 2019

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance